[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Park HS, Lee SW, Yun SU, Bae BJ, Choi HJ, Kim SY, Choi HJ, Kim WS, Kim HJ, Lee KY: Atypical thymoma (World Health Organization Type B3) with neuroendocrine differentiation combined with hyperparathyroidism. J Thorac Oncol; 2010 Sep;5(9):1490-1
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical thymoma (World Health Organization Type B3) with neuroendocrine differentiation combined with hyperparathyroidism.
  • [MeSH-major] Carcinoma, Neuroendocrine / complications. Cell Differentiation. Hyperparathyroidism / complications. Thymoma / complications. Thymus Neoplasms / complications
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736809.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A: Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol; 2009 Oct;22(10):1341-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
  • There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas.
  • The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3.
  • We performed a tissue microarray analysis of surgically resected thymic tumor specimens from 12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma.
  • Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas.
  • The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%.
  • Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity.
  • Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6% sensitivity and 100% specificity.
  • In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Glucose Transporter Type 1 / analysis. Thymoma / chemistry. Thymus Neoplasms / chemistry
  • [MeSH-minor] Antigens, CD5 / analysis. Antigens, Neoplasm / analysis. Biopsy. Carbonic Anhydrases / analysis. Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-18 / analysis. Mucin-1 / analysis. Predictive Value of Tests. Proto-Oncogene Proteins c-kit / analysis. Sensitivity and Specificity. Thymectomy. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648882.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Glucose Transporter Type 1; 0 / KRT18 protein, human; 0 / Keratin-18; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / SLC2A1 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


3. Pedersini R, Vattemi E, Lusso MR, Mazzoleni G, Ebner H, Graiff C: Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report. Tumori; 2008 Nov-Dec;94(6):849-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report.
  • AIMS AND BACKGROUND: Advanced chemorefractory epithelial thymic tumors are still a challenge in clinical oncology.
  • A therapeutic approach targeting a key molecular pathway could be the ideal solution in a neoplasm that can overexpress epidermal growth factor receptor (EGFR) in the epithelial component.
  • METHODS: A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor.
  • CONCLUSION: This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.
  • [MeSH-major] Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Thymoma / drug therapy. Thymus Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267104.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


Advertisement
4. Ito J, Sekiya M, Miura K, Yoshimi K, Suzuki T, Seyama K, Izumi H, Uekusa T, Takahashi K: Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone. Intern Med; 2009;48(12):1061-4
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone.
  • The patient was 54-year-old woman diagnosed as recurrent invasive thymoma (type B3; WHO classification).
  • The combination of octreotide and prednisolone should be considered as one of the choices of treatment in patients with recurrent thymoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Octreotide / therapeutic use. Prednisolone / therapeutic use. Somatostatin / analogs & derivatives. Thymoma / drug therapy. Thymus Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525599.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; RWM8CCW8GP / Octreotide; CISCA protocol
  •  go-up   go-down


5. Shiraishi J, Nomori H, Orikasa H, Mori T, Yamazaki K: Atypical thymoma (WHO B3) with neuroendocrine differentiation: report of a case. Virchows Arch; 2006 Aug;449(2):234-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical thymoma (WHO B3) with neuroendocrine differentiation: report of a case.
  • We report a case of type-B3 thymoma manifesting neuroendocrine differentiation.
  • This is a unique case of thymoma with neuroendocrine differentiation, and to the best of our knowledge this is the first such case ever reported.
  • [MeSH-major] Neurosecretory Systems / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1059-66 [9737237.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):330-8 [9563781.001]
  • [Cites] Am J Pathol. 1990 Jan;136(1):123-9 [2297042.001]
  • [Cites] Histopathology. 2000 Jul;37(1):19-26 [10931214.001]
  • [Cites] J Korean Med Sci. 1993 Dec;8(6):458-63 [8179834.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):613-30 [6295194.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):985-94 [11598168.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1998;46(4):253-7 [9779292.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):345-50 [10705813.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):55-61 [9212731.001]
  • (PMID = 16673117.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD56; 0 / CD1a antigen
  •  go-up   go-down


6. Azuma Y, Shiga K, Ishii R, Yamaguchi T, Niwa F, Nakagawa M: Polymyositis with atypical pathological features associated with thymic carcinoma. Intern Med; 2009;48(3):163-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymyositis with atypical pathological features associated with thymic carcinoma.
  • Remarkably, MHC-I antigen was expressed in the muscle membrane and most of the inflammatory cells were CD8-positive, suggesting that class-I antigen-dependent cytotoxic T-cells played a crucial role in the muscle pathology, which supported a diagnosis of polymyositis rather than dermatomyositis.
  • Magnetic resonance imaging of his chest revealed two mediastinal tumors, which were extirpated and diagnosed as thymic carcinoma.
  • [MeSH-major] Muscle, Skeletal / pathology. Polymyositis / pathology. Thymoma / complications. Thymus Neoplasms / complications

  • Genetic Alliance. consumer health - Polymyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182427.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.3.2 / Creatine Kinase, MM Form
  •  go-up   go-down


7. Kim HK, Choi YS, Kim J, Shim YM, Han J, Kim K: Type B thymoma: is prognosis predicted only by World Health Organization classification? J Thorac Cardiovasc Surg; 2010 Jun;139(6):1431-1435.e1
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type B thymoma: is prognosis predicted only by World Health Organization classification?
  • OBJECTIVE: The prognostic relevance of subtypes within type B thymomas is controversial.
  • The objective of this study was to evaluate the utility of World Health Organization (WHO) classification in patients with type B thymoma.
  • METHODS: This was a retrospective review of 100 patients who underwent thymectomy for WHO type B thymoma.
  • RESULTS: There were 22 type B1 tumors, 43 type B2 tumors, and 35 type B3 tumors.
  • Incomplete resection occurred in 5 patients with type B1 thymoma, 8 with type B2 thymoma, and 8 with type B3 thymoma (P = .87).
  • Of the 79 patients with complete resection, tumor recurrence occurred in 1 (5.9%) patient with type B1 thymoma, 2 (5.7%) with type B2 thymoma, and 2 (7.4%) with type B3 thymoma, and all of these patients had Masaoka stage III disease.
  • Disease-free survival at 5 years was 93%, 85%, and 82% in type B1, B2, and B3, respectively (B1 vs B2; P = .79; B2 vs B3; P = 0.6).
  • CONCLUSIONS: Tumor recurrence was significantly associated with advanced Masaoka stage regardless of the WHO subtype of type B thymomas.
  • Given the heterogeneity of WHO type B thymomas, Masaoka stage should always be considered when predicting prognosis and planning adjuvant treatment for patients with type B thymomas.
  • [MeSH-major] Thymoma / classification. Thymoma / surgery. Thymus Neoplasms / classification. Thymus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20038470.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Marandino F, Zoccali C, Salducca N, Marino M, Visca P: Ectopic primary type A thymoma located in two thoracic vertebras: a case report. BMC Cancer; 2010;10:322

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic primary type A thymoma located in two thoracic vertebras: a case report.
  • Any errors occurring during this process can cause dissemination of aberrant nodules that are responsible for most atypical thymomas.
  • CASE PRESENTATION: The authors report a unusual case of type-A thymoma located in D10 and D11 vertebral bodies.The histology showed a uniform growth of short, spindle shaped, mitotically inactive cells.
  • CONCLUSIONS: The case described shows a thymic hystogenesis for spindle cell tumours.
  • [MeSH-major] Spinal Neoplasms / pathology. Thoracic Vertebrae / pathology. Thymoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2005 Oct;128(4):2893-909 [16236967.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):111-20 [11145245.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Ann Thorac Surg. 2004 Jun;77(6):2209-10 [15172308.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Can J Neurol Sci. 1990 Feb;17(1):46-8 [2311016.001]
  • [Cites] J Comput Assist Tomogr. 1991 Sep-Oct;15(5):842-4 [1885808.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):988-97 [1384372.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):304-12 [7872428.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):143-61 [3936257.001]
  • (PMID = 20573206.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2903530
  •  go-up   go-down


9. Wu M, Sun K, Gil J, Gan L, Burstein DE: Immunohistochemical detection of p63 and XIAP in thymic hyperplasia and thymomas. Am J Clin Pathol; 2009 May;131(5):689-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of p63 and XIAP in thymic hyperplasia and thymomas.
  • We subjected 23 formalin-fixed, paraffin-embedded tissue blocks (11 cases of thymic hyperplasia and 12 thymomas [3 encapsulated, 8 with capsular invasion, and 1 atypical]) to incubation with monoclonal anti-X-linked inhibitor of apoptosis protein (XIAP) (BD Biosciences, San Jose, CA) and monoclonal anti-p63 (4A4, Santa Cruz, Santa Cruz, CA).
  • We compared thymic hyperplasia with thymoma and capsulated thymoma with thymoma with capsular invasion or atypia. p63 was positive in virtually all thymic epithelial cells in hyperplasia and thymoma.
  • One atypical thymoma was XIAP-.
  • XIAP expression differed significantly between hyperplasia and thymoma (P = .0007) but not between capsulated and invasive thymomas (P = .3797).
  • p63 is consistently positive in nonneoplastic and neoplastic thymic epithelium.
  • XIAP expression in thymoma suggests a possible role in the pathogenesis of thymoma and may be helpful in differentiating thymic hyperplasia from thymoma, especially in small biopsy specimens.
  • [MeSH-major] Membrane Proteins / metabolism. Precancerous Conditions / metabolism. Thymoma / metabolism. Thymus Gland / pathology. Thymus Neoplasms / metabolism. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369629.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


10. Vural M, Abali H, Oksuzoglu B, Akbulut M: An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma. Cancer Invest; 2006 Oct;24(6):615-20
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma.
  • Although rare, thymoma is the most frequent type of malignancy in the anterior mediastinum.
  • On most occasions, radiological diagnosis is easy, owing to current imaging studies like computerized tomography.
  • Additionally, the radiological diagnosis of thymoma can be differentiated easily from malignant pleural mesothelioma in most cases.
  • However, thymoma's differentiation from lymphoma, thymic hyperplasia, or thymic remnants sometimes may pose diagnostic challenges.
  • Here, we report a case of advanced thymoma mimicking malignant pleural mesothelioma, with circumferential encasement of the lung.
  • A brief review of the literature with special reference to radiological imaging on thymoma also is presented.
  • [MeSH-major] Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982467.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Radotra B, Awasthi A, Joshi K, Das A: Histopatholgical spectrum of thymic neoplasms: twelve-year experience at a referral hospital in north India. Indian J Pathol Microbiol; 2006 Jan;49(1):1-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopatholgical spectrum of thymic neoplasms: twelve-year experience at a referral hospital in north India.
  • This study was undertaken to determine the histopathological spectrum and clinical profile of thymic neoplasms at a tertiary referral care centre.
  • Among the neoplasms there were 48 thymic epithelial tumors, 3 thymolipomas and 3 thymic carcinoids.
  • Among paraneoplastic syndromes in thymic epithelial tumours, 27 out of 48 (56.25%) cases were associated with myasthenia gravis and one case was associated with pure red cell aplasia.
  • The most frequent histological subtype was cortical thymoma (43.24%) followed by predominantly cortical (24.32%) and well-differentiated thymic carcinoma (18.92%).
  • On staging, all cases of mixed and predominantly cortical subtype were stage 1 whereas one medullary and 2 cortical thymomas and 4 well differentiated thymic carcinoma (WDTC) showed pleural and pericardial invasion (stage III).
  • This study has revealed that half of thymic epithelial tumours presented as myasthenia gravis.
  • The cortical thymoma was the most frequently encountered histologic subtype and most commonly associated with myasthenia gravis.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoma / pathology. Child. Child, Preschool. Female. Humans. India. Lipoma / pathology. Male. Middle Aged. Myasthenia Gravis. Neoplasm Staging. Red-Cell Aplasia, Pure. Thymectomy. Thymoma / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625962.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Méan M, Schaller MD, Asner S, Meylan P, Pagani JL, Tarr P, Eggimann P: Thymoma, immunodeficiency, and herpes simplex virus infections. Med Mal Infect; 2009 May;39(5):344-7
MedlinePlus Health Information. consumer health - Herpes Simplex.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma, immunodeficiency, and herpes simplex virus infections.
  • Hypogammaglobulinemia develops in 3 to 6% of patients with thymoma and this association is commonly referred to as thymoma with immunodeficiency (formerly Good syndrome).
  • We report a case of thymoma with immunodeficiency complicated by disseminated herpes simplex virus (HSV) infection and review five additional cases of HSV-related infections reported since 1966 in patients presenting with thymoma with immunodeficiency.
  • Since the risk of invasive opportunistic infections is high and the presentation atypical, lymphocyte count and total serum immunoglobulin should be measured regularly in all patients presenting with thymoma with immunodeficiency.
  • [MeSH-major] Ceftriaxone / therapeutic use. Herpes Simplex / complications. Immunologic Deficiency Syndromes / complications. Thymoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269757.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulins; 75J73V1629 / Ceftriaxone
  •  go-up   go-down


13. Sano A, Kosugi N, Kitano K, Sakamoto M, Yoshida Y, Fukami T, Murakawa T, Nakajima J: [Thymoma with synchronous pulmonary metastasis; report of a case]. Kyobu Geka; 2010 Nov;63(12):1090-3
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymoma with synchronous pulmonary metastasis; report of a case].
  • We report a resected case of thymoma with a solitary pulmonary metastasis.
  • Pathological diagnosis showed an invasive thymoma (type B3) and a pulmonary metastasis.
  • Post operative radiotherapy was administered and she is doing well 19 months following the resection.
  • Thymoma with a solitary synclonous pulmonary metastasis is rare and is classified into Masaoka stage IVb.
  • Generally, thymoma cases with distant metastasis are not indication for operation.
  • [MeSH-major] Lung Neoplasms / secondary. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066855.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Yutaka Y, Omasa M, Shikuma K, Okuda M, Taki T: Spontaneous regression of an invasive thymoma. Gen Thorac Cardiovasc Surg; 2009 May;57(5):272-4
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of an invasive thymoma.
  • Although there are many reports of spontaneous regression of noninvasive thymoma, there are no reports of spontaneous regression of an invasive thymoma.
  • The tissue obtained by video-assisted thoracic surgery suggested a diagnosis of invasive thymic carcinoma.
  • On pathology, the diagnosis was thymoma type B3.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gen Thorac Cardiovasc Surg. 2010 Apr;58(4):212-3 [20401719.001]
  • [Cites] Kyobu Geka. 2003 Aug;56(9):801-5 [12931595.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):867-71 [15198359.001]
  • [Cites] J Surg Oncol. 1981;17(3):201-9 [6166811.001]
  • [Cites] Histopathology. 1994 Sep;25(3):289-91 [7821901.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 May;57(5):272-4 [19440828.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):441-6 [2328213.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1086-90 [11474295.001]
  • [Cites] J Postgrad Med. 2004 Apr-Jun;50(2):94-7 [15235201.001]
  • (PMID = 19440828.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Sonobe S, Miyamoto H, Izumi H, Nobukawa B, Futagawa T, Yamazaki A, Oh T, Uekusa T, Abe H, Suda K: Clinical usefulness of the WHO histological classification of thymoma. Ann Thorac Cardiovasc Surg; 2005 Dec;11(6):367-73
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of the WHO histological classification of thymoma.
  • PURPOSE: Rosai et al. published the World Health Organization (WHO) classification of thymic epithelial tumors in 1999, and its clinical usefulness seems to be established.
  • It is our purpose to find the clinically relevant diagnostic points in the WHO Histological Classification of Thymoma.
  • We assessed overall survival and recurrence-free rate calculated for each tumor type in the WHO classification compared with those of tumors classified by the Masaoka system.
  • RESULTS: The thymic epithelial tumors in this series comprised 10 type A, 15 type AB, 18 type B1, 21 type B2, 33 type B3, and 3 type C tumors according to the WHO classification.
  • The 15-year recurrence-free rate was 100% for type A, AB and B1, while the rates for types B2 and B3 were 66.7% and 54.5%, respectively.
  • The 10-year recurrence-free rate was 66.7% for type C.
  • The 15-year recurrence-free rate of the 64 patients with type A, AB, B1, and B2 thymomas was significantly higher from that of the 33 patients with type B3 thymoma (p=0.0026).
  • CONCLUSION: When using the WHO classification, it is critical to distinguish type B3 thymoma from other tumor types.
  • [MeSH-major] Thymoma / classification. Thymoma / pathology. Thymus Neoplasms / classification. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401984.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Pantidou A, Kiziridou A, Antoniadis T, Tsilikas C, Destouni C: Mediastinum thymoma diagnosed by FNA and ThinPrep technique: a case report. Diagn Cytopathol; 2006 Jan;34(1):37-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinum thymoma diagnosed by FNA and ThinPrep technique: a case report.
  • Thymoma is a primary tumor of the thymus epithelial cells.
  • It may be asymptomatic or accompanied with atypical clinical symptoms or paraneoplastic syndromes, such as myasthenia gravis.
  • The invasion of the capsule or the adjacent tissues is the major diagnostic criterion for the malignant behavior of these tumors.
  • This is an interesting case of thymoma diagnosed by fine-needle aspiration biopsy (FNA) and ThinPrep technique, in a 54-year-old female patient with a history of gastric adenocarcinoma.
  • Cytology of the mediastinum mass revealed a mixed population of epithelial cells and lymphocytes.
  • The tumor was excised and the histopathological examination supported the cytological diagnosis.
  • Thymomas commonly constitute a problem in differential diagnosis of mediastinum masses.
  • [MeSH-major] Biopsy, Fine-Needle. Mediastinal Neoplasms / diagnosis. Thymoma / diagnosis. Thymoma / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Female. Histocytological Preparation Techniques. Humans. Middle Aged. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355373.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chen YD, Feng QF, Lu HZ, Mao YS, Zhou ZM, Ou GF, Wang M, Zhao J, Zhang HX, Xiao ZF, Chen DF, Liang J, Zhai YR, Wang LH, He J: Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1400-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection.
  • PURPOSE: To determine whether patients with Masaoka stage II thymoma benefit from adjuvant radiation therapy after complete tumor resection.
  • METHODS AND MATERIALS: A total of 107 patients with stage II thymoma who underwent complete resection of their tumors between September 1964 and October 2006 were retrospectively analyzed.
  • On univariate analysis, patients with type B3 thymomas had the lowest disease-free survival rates among all subtypes (p = 0.001), and patients with large thymomas (>7 cm) had lower disease-specific survival rates than those with small tumors (<7 cm) (p = 0.017).
  • On multivariate analysis, histological type (type B3) thymoma was a significant independent prognostic factor.
  • CONCLUSIONS: Adjuvant radiotherapy after complete tumor resection for patients with stage II thymoma did not significantly reduce recurrence rates or improve survival rates.
  • Histological type (type B3) thymoma was a significant independent prognostic factor.
  • [MeSH-major] Thymoma / radiotherapy. Thymoma / surgery. Thymus Neoplasms / radiotherapy. Thymus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20378264.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Niimi T, Gotoh M: [Cystic thymoma; report of a case]. Kyobu Geka; 2009 Feb;62(2):165-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic thymoma; report of a case].
  • We present a case of a 33-year-old man with a noninvasive thymoma undergoing extensive cystic degeneration.
  • A cystic thymoma was suggested.
  • Histopathological examination revealed a World Health Organization (WHO) type B3 thymoma with foci of hemorrhage, necrosis and cystic degeneration, and absence of an epithelial lining of the cyst.
  • [MeSH-major] Mediastinal Cyst / surgery. Thymoma / surgery. Thymus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202941.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Kono M, Fujii M, Akamatsu T, Suda T, Chida K: [A case of Pneumocystis jiroveci pneumonia that presented with cavity and cystic changes in a malignant thymoma patient]. Nihon Kokyuki Gakkai Zasshi; 2008 Apr;46(4):297-301
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Pneumocystis jiroveci pneumonia that presented with cavity and cystic changes in a malignant thymoma patient].
  • A 53-year-old man had received various chemotherapy and steroid treatments for malignant thymoma.
  • We reported this case of a non-HIV patient with atypical images demonstrating Pneumocystis jiroveci pneumonia.
  • [MeSH-major] Pneumocystis jirovecii. Pneumonia, Pneumocystis / complications. Pneumonia, Pneumocystis / pathology. Thymoma / complications. Thymus Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516993.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Inoue M, Kojima Y, Shinde A, Satoi H, Makino F, Kanda M, Shibasaki H: [Concurrence of myasthenia gravis, polymyositis, thyroiditis and eosinophilia in a patient with type B1 thymoma]. Rinsho Shinkeigaku; 2007 Jul;47(7):423-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrence of myasthenia gravis, polymyositis, thyroiditis and eosinophilia in a patient with type B1 thymoma].
  • This finding is atypical for polymyositis.
  • X-ray and CT of chest showed a mass lesion in the left pulmonary hilum, which was histologically diagnosed as type B1 thymoma.
  • Thus, the present case had myasthenia gravis, polymyositis, thyroidititis and eosinophilia associated with type B1 thymoma.
  • [MeSH-major] Eosinophilia / etiology. Myasthenia Gravis / etiology. Polymyositis / etiology. Thymoma / diagnosis. Thymus Neoplasms / diagnosis. Thyroiditis / etiology


21. Yamazaki H, Tateyama H, Asai K, Fukai I, Fujii Y, Tada T, Eimoto T: Glia maturation factor-beta is produced by thymoma and may promote intratumoral T-cell differentiation. Histopathology; 2005 Sep;47(3):292-302
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glia maturation factor-beta is produced by thymoma and may promote intratumoral T-cell differentiation.
  • METHODS AND RESULTS: We investigated the expression of GMFB by immunohistochemistry in 86 cases of thymoma classified into five type A, 35 type AB, 11 type B1, 26 type B2, and nine type B3 thymomas according to the World Health Organization classification system.
  • Immunohistochemically, GMFB expression was observed in one (20%) of type A, 32 (80%) of type AB, all (100%) of type B1 and B2, and eight (89%) of type B3 thymoma with statistically significant differences between type A and type AB, type B1, or type B2 thymoma, and between type B3 and type AB or type B2 thymoma.
  • CONCLUSIONS: The present study suggests that T-cell development in thymoma may be maintained partly by GMFB produced by the tumour cells.
  • [MeSH-major] Cell Differentiation. Glia Maturation Factor / analysis. T-Lymphocytes / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115230.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glia Maturation Factor; 0 / RNA, Messenger
  •  go-up   go-down


22. Triggiani V, Guastamacchia E, Lolli I, Troccoli G, Resta F, Sabbà C, Ruggieri N, Tafaro E: Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature. Immunopharmacol Immunotoxicol; 2006;28(2):377-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature.
  • There are few cases described in the world literature reporting an association of thymoma (with myasthenia gravis or not) with hyperparathyroidism.
  • In these cases the hyperparathyroidism was due to the presence of an adenoma or hyperplasic parathyroid tissue either in the cervical region or in an ectopic intrathymic location.(12345) In other cases the syndrome of hypercalcemia was due to the secretion of parathyroid-related protein (PTHRP) (6) or parathyroid hormone (PTH) (7) by the thymoma itself.
  • We report the first case, at the best of our knowledge, of a wide invasive malignant thymoma (type B3), associated with myasthenia gravis and hyperparathyroidism caused by parathyroid adenoma.


23. Ströbel P, Marino M, Feuchtenberger M, Rouzière AS, Tony HP, Wulbrand U, Förster R, Zettl A, Lee Harris N, Kreipe H, Laeng RH, Müller-Hermelink HK, Marx A: Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development. J Pathol; 2005 Sep;207(1):72-82
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development.
  • Although thymic follicular lymphoid hyperplasia (TFH) is commonly associated with myasthenia gravis (MG), lymphoma is not a complication of this condition.
  • The present paper reports a high frequency of monoclonal B-cell populations (6 of 18 cases; 33%) in micronodular thymoma (MNT), a peculiar thymic epithelial neoplasm with a B-cell-rich stroma, while B cells were consistently polyclonal in TFH (25 cases) and other types of thymomas (15 cases) (p < 0.001).
  • Sequencing of the monoclonal IgH chain revealed partially overlapping VDJ gene usage in MNT and thymic mucosa-associated lymphoid tissue (MALT) lymphomas.
  • The neoplastic epithelium of MNTs, but not of TFH and other types of thymoma, expressed high levels of dendritic cell, T-cell, and B-cell chemoattractants, such as CCL18, CCR6, and CCL20.
  • It is concluded that abnormal chemokine expression in an epithelial tumour, MNT, can promote the recruitment of MALT, the emergence of monoclonal B cells, and, eventually, the subsequent development of mediastinal lymphomas.
  • [MeSH-major] Chemokines / metabolism. Mediastinal Neoplasms / immunology. Neoplasms, Second Primary / immunology. Thymoma / immunology. Thymus Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocyte Subsets / immunology. Dendritic Cells / pathology. Epithelial Cells / pathology. Female. Gene Rearrangement, B-Lymphocyte. Humans. Hyperplasia / immunology. Immunophenotyping. In Situ Hybridization, Fluorescence. Macrophages / pathology. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocyte Subsets / immunology. Thymus Gland / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 15965907.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines
  •  go-up   go-down


24. Di Tommaso L, Kuhn E, Kurrer M, Zettl A, Marx A, Müller-Hermelink HK, Roncalli M, Rosai J: Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases. Am J Surg Pathol; 2007 Aug;31(8):1161-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases.
  • Thymic carcinomas are rare malignant neoplasms which comprise several histologic subtypes.
  • Adenoid cystic carcinoma (ACC) is included among these subtypes even if it has never been formally reported.
  • We evaluated the clinical, radiologic, morphologic, immunohistochemical, and genetic features of 4 cases of thymic neoplasms with ACC-like features retrieved from the authors' consult files.
  • The clinical history (no evidence of ACC in other sites), radiologic findings (a mass in the thymic region), and morphologic features (residual thymic tissue at the periphery of the neoplasm) strongly supported their primary thymic nature.
  • One patient is alive and well after 20 months, 1 died of another cause 5 years later, and 2 were lost at follow-up.
  • Exceptionally, primary thymic tumors may exhibit histologic features resembling those of ACC of salivary glands.
  • They may be well circumscribed and cytologically bland or invasive and cytologically atypical.
  • We have interpreted them as a microscopic subtype of well-differentiated thymic carcinoma of low-grade malignancy, an impression supported by the admittedly limited follow-up information.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667537.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


25. Du J, Zhou XJ, Yin HL, Lu ZF, Zhou HB: [Expression of CD20 in thymomas and its clinical implication]. Zhonghua Bing Li Xue Za Zhi; 2010 Sep;39(9):611-4
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and seventy-nine cases of thymoma were enrolled into the study.
  • The histologic diagnosis was reviewed by two experienced pathologists on the basis of the 2004 WHO classification.
  • RESULTS: Amongst the 102 cases studied, 7 cases belonged to type A thymoma, 32 cases type AB thymoma, 17 cases type B1 thymoma, 15 cases type B2 thymoma, 17 cases type B3 thymoma and 14 cases thymic carcinoma.
  • The expression rates of CD20 in neoplastic epithelial cells of type A, type AB, type B1, type B2 and type B3 thymomas and thymic carcinomas were 3/7, 84.4% (27/32), 1/17, 2/15, 0/17, 0/14, respectively.
  • CONCLUSIONS: The neoplastic epithelial cells in cases of type A and type AB thymoma, as well as few cases of type B1 and B2 thymoma, express CD20.
  • Type AB thymomas may be originated from different populations of cells, rather than a simple admixture of type A and B thymoma cells.
  • [MeSH-major] Antigens, CD20 / metabolism. Thymoma / immunology. Thymoma / pathology. Thymus Neoplasms / immunology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Child. Epithelial Cells / immunology. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Myasthenia Gravis / complications. Myasthenia Gravis / immunology. Myasthenia Gravis / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092589.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


26. Ma YQ, Miao N, Abulajiang G, Li QX, Liu X, Zhang W, Wang CF, Wang J: [Clinicopathologic analysis of 52 cases of thymic epithelial tumor]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):249-54
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 52 cases of thymic epithelial tumor].
  • OBJECTIVE: To study the clinicopathologic characteristics of thymic epithelial tumors and to evaluate the diagnostic reproducibility and clinical relevance of the 2004 WHO histologic classification system.
  • METHODS: The morphology and immunophenotype of 52 cases of thymic epithelial tumor were reviewed.
  • RESULTS: Of the 52 cases studied, 45 were thymomas and 7 were thymic carcinomas.
  • Amongst the 45 cases of thymoma, 6 (13.4%) were type A, 15 (33.3%) were type AB, 4 (8.9%) were type B1, 9 (20.0%) were type B2, 9 (20.0%) were type B3 and 2 (4.4%) were metaplastic thymoma.
  • Amongst the 7 cases of thymic carcinoma, 6 were squamous cell carcinomas and 1 was neuroendocrine carcinoma.
  • Thirteen cases (25.0%) of thymoma were associated with myasthenia gravis.
  • All cases of type A, AB and B1 thymoma and most cases of B2 thymoma appeared as well-defined homogeneous mass, whereas a few cases of type B2 thymoma and most cases of type B3 thymoma and thymic carcinoma were poorly demarcated and heterogeneous.
  • The histologic subtypes of thymic epithelial tumors significantly correlated with the clinical stages (chi(2) = 32.5, P < 0.01).
  • CONCLUSIONS: The 2004 revision of WHO histologic classification system for thymic epithelial tumors shows a high degree of reproducibility.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / analysis. Antigens, CD20 / metabolism. Antigens, CD5 / metabolism. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / radiography. Female. Follow-Up Studies. Humans. Keratins / immunology. Male. Middle Aged. Myasthenia Gravis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Thymic epithelial tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654124.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antigens, CD5; 68238-35-7 / Keratins
  •  go-up   go-down


27. Jiao X, Yin HL, Lu ZF, Zhao YC, Zhou XJ: [Histologic subtyping and prognosis of thymoma: a study of 108 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Jul;37(7):445-9
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histologic subtyping and prognosis of thymoma: a study of 108 cases].
  • OBJECTIVE: To study the prognostic and clinical relevance of histologic subtyping of thymoma according to the World Health Organization (WHO) classification.
  • METHODS: The clinicopathologic features of 108 patients with thymoma removed surgically were retrospectively reviewed.
  • The histologic diagnosis of the tumors was made on the basis of 2004 WHO classification by two experienced pathologists.
  • RESULTS: According to WHO classification, there were 7 cases (6.5%) of type A thymoma, 19 cases (17.6%) of type AB thymoma, 23 cases (21.3%) of type B1 thymoma, 19 cases (17.6%) of type B2 thymoma, 27 cases (25.0%) of type B3 thymoma and 13 cases (12.0%) of type C thymoma.
  • The 5-year survival rates of type A, AB, B1, B2 and B3 thymoma cases were 100%, 100%, 93%, 83% and 43%, respectively; while the 10-year survival rates were 100%, 100%, 81%, 70% and 33%, respectively.
  • The median survival time of type C thymoma was 62.5 months.
  • Type B2 and B3 thymoma cases had an intermediate prognostic ranking in comparison with type C thymoma and other groups (P = 0.000).
  • On the other hand, the WHO subtype (type A to B1 versus type B2 to B3 versus type C) and completeness of resection could predict the tumor-related survival.
  • CONCLUSIONS: The Masaoka tumor stage is the single most important prognostic factor of thymoma.
  • The classification of thymoma may also reflect the clinical behavior of the tumor.
  • Type A, AB and B1 thymomas belong to the low-risk group, while type B2 and B3 thymomas have an intermediate prognostic ranking.
  • Type C thymoma carries the worst prognosis.
  • [MeSH-major] Myasthenia Gravis / etiology. Prognosis. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035114.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Ito Y, Miyauchi A, Arai K, Nozawa R, Miya A, Kobayashi K, Nakamura Y, Kakudo K: Usefulness of S100A9 for diagnosis of intrathyroid epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE). Pathology; 2006 Dec;38(6):541-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100A9 for diagnosis of intrathyroid epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE).
  • AIMS: Intrathyroid epithelial tumour (ITET)/carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumour, which is thought to originate from ectopic thymic tissue in the thyroid.
  • The differential diagnosis between ITET/ CASTLE and squamous cell carcinoma (SCC) or undifferentiated carcinoma with squamoid component (UC-SCC) is very important, because ITET/CASTLE shows a far better prognosis than SCC or UC-SCC.
  • In this study, we investigated the usefulness of S100A9, a marker of SCC and squamous cell epithelia, for diagnosis of ITET/CASTLE.
  • METHODS: We immunohistochemically investigated S100A9 expression in 23 ITET/CASTLEs, 26 SCCs, and 19 UC-SCCs, as well as eight thymomas and 12 normal thymic tissues.
  • RESULTS: All thymomas and thymic tissues showed a small number of S100A9-expressing cells in a scattered pattern in accordance with Hassall corpuscles.
  • Twenty-one of 23 ITET/ CASTLEs showed the same pattern as thymomas or thymic tissues, while 14 SCCs and 15 UC-SCCs showed diffuse and laminated positivity of S100A9.
  • The positive predictive value and specificity of S100A9 for diagnosis of ITET/CASTLE was 91.3 and 93.9%, respectively, and sensitivity was 75.0%.
  • [MeSH-major] Calgranulin B / metabolism. Neoplasms, Glandular and Epithelial / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Cell Differentiation. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Predictive Value of Tests. Thymus Gland / metabolism. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393982.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calgranulin B
  •  go-up   go-down


29. Fox T, Simon EL, Elder E, Riffenburgh RH, Johnstone PA: Free breathing gated delivery (FBGD) of lung radiation therapy: analysis of factors affecting clinical patient throughput. Lung Cancer; 2007 Apr;56(1):69-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of patients had lung cancer (n=12) with single cases of adrenal metastasis, thymoma, and atypical carcinoid.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196299.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 5P60-MD000525
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


30. Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos DS, Papapetropoulos T, Petsas T, Dougenis D: Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo; 2007 Jan-Feb;21(1):123-32
MedlinePlus Health Information. consumer health - Myasthenia Gravis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathology of the thymus showed: hyperplasia-26, atrophy-8, thymoma B1 and B2 type-9, thymoma B3 type (well differentiated thymic carcinoma)-3.
  • Paraffin sections of thymic tissue were subjected to: a) immunohistochemistry (bax, bcl-2, caspase-3 protein);.

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354625.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


31. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Nakata T, Sunamori M, Handa M, Kondo T, Sasano H: Estrogen inhibits cell proliferation through in situ production in human thymoma. Clin Cancer Res; 2005 Sep 15;11(18):6495-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen inhibits cell proliferation through in situ production in human thymoma.
  • PURPOSE: We showed previously estrogen receptor (ER) alpha as an independent prognostic marker in human thymoma.
  • EXPERIMENTAL DESIGN: We examined estrogen production using primary cultures of human thymoma epithelial cells (TEC), intratumoral estradiol (E(2)) concentrations, and status of these enzymes above using immunohistochemistry or semiquantitative reverse transcription-PCR.
  • Intratumoral E(2) concentrations were inversely correlated with EST, positively correlated with STS or 17beta-HSD type 1, and significantly higher in lower-grade or early-stage thymoma.
  • STS and/or 17beta-HSD type 1 status was inversely correlated with Ki-67 labeling index and associated with lower histologic grade or early clinical stages.
  • CONCLUSIONS: E(2) inhibits proliferation of TEC through ERalpha, which suggests that E(2) may be effective in treatment of thymoma, especially inoperable tumor, possibly through suppressing its cell proliferation activity.
  • EST status is a potent prognostic factor in thymoma through inactivating estrogens.
  • In situ estrogen synthesis through intracrine mechanism therefore may play important roles in tumorigenesis and/or development of thymoma through regulation of cell proliferation in an intracrine manner.
  • [MeSH-major] Cell Proliferation / drug effects. Estrogens / pharmacology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] 17-Hydroxysteroid Dehydrogenases / genetics. 17-Hydroxysteroid Dehydrogenases / metabolism. Adult. Aged. Aromatase / genetics. Aromatase / metabolism. Dose-Response Relationship, Drug. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Estradiol / biosynthesis. Estrogen Receptor alpha / metabolism. Estrone / biosynthesis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Steryl-Sulfatase / genetics. Steryl-Sulfatase / metabolism. Sulfotransferases / genetics. Sulfotransferases / metabolism. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166425.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.14.14.1 / Aromatase; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.4 / estrone sulfotransferase; EC 3.1.6.2 / Steryl-Sulfatase
  •  go-up   go-down


32. Ito Y, Miyauchi A, Nakamura Y, Miya A, Kobayashi K, Kakudo K: Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with Member Institutes of The Japanese Society of Thyroid Surgery. Am J Clin Pathol; 2007 Feb;127(2):230-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with Member Institutes of The Japanese Society of Thyroid Surgery.
  • Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor having histopathologic features similar to those of squamous cell carcinoma of the thyroid and other organs and a more favorable prognosis.
  • It is thought to originate from ectopic thymic tissue or embryonic thymic rest in or adjacent to the thyroid.
  • The sensitivity and specificity of the pathologic diagnosis of ITET/CASTLE by immunohistochemical staining with CD5, a marker of carcinoma of thymic origin, were 82% and 100%, respectively.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210519.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


33. Thakur A, Sebag F, Micco CD, Slotema E, Henry FJ: Ectopic cervical thymoma mimicking as papillary thyroid carcinoma: a diagnostic dilemma. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):305-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic cervical thymoma mimicking as papillary thyroid carcinoma: a diagnostic dilemma.
  • Predominant epithelial thymoma can be misdiagnosed as papillary thyroid carcinoma on fine needle aspiration and lymph node metastasis of epithelial tumor on frozen section.
  • Predominantly lymphocytic thymomas have often been misinterpreted as Hashimoto's thyroiditis or malignant lymphoma, either by fine needle aspiration or on frozen section analysis.
  • We present such rare case of ectopic cervical thymoma mimicking as papillary thyroid carcinoma.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Thymoma / diagnosis. Thymoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Histocytochemistry. Humans. Microscopy. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551539.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


34. Yoshino N, Kubokura H, Yamauchi S, Oaki Y, Koizumi K, Shimizu K: Type B3 thymic epithelial tumor in an adolescent detected by immunohistochemical staining for CD5, CD99, and KIT (CD117): a case report. Ann Thorac Cardiovasc Surg; 2009 Oct;15(5):324-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type B3 thymic epithelial tumor in an adolescent detected by immunohistochemical staining for CD5, CD99, and KIT (CD117): a case report.
  • The tumor tissue showed a cobblestone-like proliferation of atypical cells containing a discrete nucleolus that were aligned in an epithelial fashion against mainly lymphocytic inflammatory cells in the background; also shown were undifferentiated tumor cells with epithelioid characteristics.
  • The lesion was therefore diagnosed to be a type B3 thymic epithelial tumor.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD5 / analysis. Cell Adhesion Molecules / analysis. Immunohistochemistry. Proto-Oncogene Proteins c-kit / analysis. Thymoma / immunology. Thymus Neoplasms / immunology

  • Genetic Alliance. consumer health - Thymic epithelial tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901887.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD5; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


35. Striano P, Tortora F, Evoli A, Palmieri G, Elefante A, Zara F, Tarr PE, Striano S: Periodic myoclonus due to cytomegalovirus encephalitis in a patient with good syndrome. Arch Neurol; 2007 Feb;64(2):277-9
MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Good syndrome (GS) refers to a constellation of thymoma and adult-onset immunodeficiency characterized by low or absent B cells, hypogammaglobulinemia, and variable defects in cell-mediated immunity with an inverted CD4/CD8(+) T-cell ratio.
  • SETTING: Outpatient neurology clinic at a university medical center.
  • RESULTS: Five years previously, the patient had undergone resection of a pathologically confirmed epithelial thymoma.
  • Quantitative CMV polymerase chain reaction of the serum and cerebrospinal fluid showed strongly positive results (1:10 000), allowing the diagnosis of CMV encephalitis.
  • Opportunistic CMV infection should be considered early in the evaluation of patients with GS or a history of thymoma who develop unusual neurological symptoms.

  • Genetic Alliance. consumer health - Good Syndrome.
  • Genetic Alliance. consumer health - Myoclonus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296846.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. de Souza A, Gibson LE, Wada DA, Yi ES, Medeiros F, Camilleri MJ, el-Azhary R, Micallef IN: Resolution of CD8+ lymphomatoid papulosis after surgical excision of the type AB-thymoma. Am J Dermatopathol; 2009 Jul;31(5):475-9
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of CD8+ lymphomatoid papulosis after surgical excision of the type AB-thymoma.
  • The type AB thymoma is an epithelial neoplasm composed of both type A (lymphocyte-poor) and type B (lymphocyte-rich) areas.
  • We describe a patient whose type B LyP CD8 lesions completely resolved after surgical removal of type AB thymoma.
  • The chemokine profile was similar in both tissues: thymus- and activation-regulated chemokine and CCR4 were focally positive in the thymoma.
  • Monokine induced by interferon-g (Mig) staining showed strong positivity in the dermal lymphocytes and in localized areas of the thymoma, but an immunostain for the Mig receptor (CXCR3) highlighted only a few scattered cells in both tissues (less than 3%).
  • In summary, we report the association of a CD30-negative CD8-predominant LyP and a type AB thymoma, with similar chemokine profiles.
  • The rarity of both conditions and the precise regression of LyP after removal of the thymoma argue against a coincidental observation.
  • We recommend that a search for thymoma be included in the workup of LyP.
  • [MeSH-major] Lymphomatoid Papulosis / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542925.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokines; 0 / Receptors, Chemokine
  •  go-up   go-down


37. Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI: Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer; 2008 Dec;62(3):321-5
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of gene mutations in KIT-positive thymic epithelial tumors.
  • However, the role of KIT expression in thymic carcinoma is not fully understood.
  • METHODS: Thymic epithelial tumors from 37 patients (17 thymic carcinomas and 20 thymomas) were examined.
  • RESULTS: KIT- and CD5-positive staining was observed only in thymic carcinoma.
  • Percentage of positive staining was 100% in squamous cell carcinoma, with no positive staining in other histologies, including atypical carcinoid.
  • Mutation analysis of the KIT gene was performed in 11 squamous cell carcinomas, 1 adenocarcinoma and 1 adenosquamous cell carcinoma.
  • CONCLUSIONS: Squamous cell carcinoma of the thymus frequently expressed KIT and CD5 proteins, whereas other tumors did not.
  • Unlike GIST, overexpression of KIT does not necessarily indicate gene mutation in thymic carcinoma.
  • KIT and CD5 appear useful for evaluating and subtyping thymic epithelial tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Mutation / genetics. Proto-Oncogene Proteins c-kit / genetics. Thymoma / genetics. Thymus Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486988.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


38. Liu JM, Wang LS, Huang MH, Hsu WH, Yen SH, Shiau CY, Li AF, Tiu CM, Tseng SW, Huang BS: Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer; 2007 Feb 1;109(3):502-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia.
  • BACKGROUND: Microsatellite studies in histologic types B3 and C thymic neoplasia detected gains on chromosome 17q, which contains the Her-2/neu and its juxtaposed topoisomerase 2alpha (T2alpha) genes.
  • The study aimed to evaluate their impact on tumor biology and survival of advanced thymic neoplasia patients.
  • METHODS: From 1991 to 2005, 36 consecutive stage IV thymic carcinoma patients were treated, 18 men and 18 women, aged 11 to 84 years.
  • There were 22 thymic carcinoma, 13 type B3, and 1 type B2 thymoma.
  • RESULTS: T2alpha gene amplification was detected in 4 of 14 thymic carcinoma and 1 of 15 type B3 thymoma.
  • Three thymic carcinoma patients had Her-2/neu coamplification and these 3 patients had rapidly growing tumor and extensive disease at initial diagnosis.
  • Overall survival was significantly prolonged if the tumor was resectable (P = .001), of type B3 histology (P = .0039), and had no Her-2 gene amplification (P = .0081).
  • CONCLUSION: T2alpha and Her-2/neu genes play a pivotal role in the tumor biology, CAP response, and survival of advanced thymic neoplasia patients.
  • [MeSH-major] Antigens, Neoplasm / physiology. DNA Topoisomerases, Type II / physiology. DNA-Binding Proteins / physiology. Thymus Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17154178.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Schönfeldt-Lecuona C, Freudenmann RW, Tumani H, Kassubek J, Connemann BJ: Acute psychosis with a mediastinal carcinoma metastasis. Med Sci Monit; 2005 Jan;11(1):CS6-8
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute psychosis with a mediastinal carcinoma metastasis.
  • BACKGROUND: Reversible schizophrenia-like syndromes have been reported to occur with small-cell carcinoma of the lung, thymoma, and hematological disorders.
  • Extensive checkup revealed an isolated mediastinal metastasis of an undifferentiated carcinoma.
  • After removal of the metastasis, the psychosis remitted rapidly and completely, and the patient remained well on follow-up.
  • CONCLUSIONS: Paraneoplastic syndromes may clinically present as acute psychoses and, in late-onset schizophreniform disorders with an atypical presentation, performing a tumor search should always be considered.

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Olanzapine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614198.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; 614OI1Z5WI / Valproic Acid; 8915147A2B / Perazine
  •  go-up   go-down


40. Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J: Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg; 2010 Mar;89(3):912-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma.
  • BACKGROUND: Thymic carcinoma is a rare tumor.
  • Limited data are available regarding the effectiveness of treatment and the prognosis of thymic carcinoma.
  • METHODS: The study retrospectively reviewed 21 patients (15 men, 6 women) with thymic carcinoma who had undergone resection at Niigata University Hospital.
  • Histologic subtypes were squamous cell carcinoma in 14 patients, adenocarcinoma in 2, atypical carcinoid in 3, and undifferentiated carcinoma in 2.
  • CONCLUSIONS: The surgical outcome of patients with thymic carcinoma depends on the Masaoka stage and histologic grade.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20172153.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Arora R, Gupta R, Sharma A, Dinda AK: Primary neuroendocrine carcinoma of thymus: a rare cause of Cushing's syndrome. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):148-51
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary neuroendocrine carcinoma of thymus: a rare cause of Cushing's syndrome.
  • Thymomas constitute majority of the thymic neoplasms.
  • In contrast, neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) of thymus are extremely rare.
  • Thymic carcinoids may present rarely with Cushing's syndrome due to the ectopic production of adrenocorticotropic hormone (ACTH).
  • We describe three cases of rare atypical carcinoid tumor (neuroendocrine carcinoma) of the thymus.
  • The features suggested a diagnosis of atypical carcinoid tumor in all the three cases.
  • Atypical carcinoid (neuroendocrine carcinoma, well-differentiated and moderately-differentiated) of the thymus is a rare thymic tumor which carries a worse prognosis compared to thymoma and requires aggressive therapy.
  • Hence, an accurate diagnosis is essential.
  • [MeSH-major] Carcinoma, Neuroendocrine / complications. Carcinoma, Neuroendocrine / diagnosis. Cushing Syndrome / etiology. Thymus Gland / pathology. Thymus Neoplasms / complications. Thymus Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090249.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


42. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R: Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest; 2005 Jul;128(1):140-4
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
  • STUDY OBJECTIVES: It is sometimes very difficult both clinically and pathologically to distinguish thymic epithelial tumors from primary lung carcinoma with massive anterior mediastinal involvement.
  • The expression of KIT (CD117) in thymic epithelial tumors was investigated in order to evaluate its usefulness as a marker supporting differential diagnosis and choice of therapy.
  • METHODS: We examined the immunohistochemical expression of KIT in 70 resected thymic epithelial tumors (thymomas, 50; thymic carcinomas, 20) that had been reclassified on the basis of the World Health Organization histologic classification system.
  • We also compared the expression of KIT and CD5 in 20 thymic carcinomas with their expression in 20 resected pulmonary squamous cell carcinomas that were spreading directly into the mediastinum.
  • RESULTS: Of the 50 thymomas, only 2 (4%) showed positive immunoreactivity for KIT (type A thymoma, 1; type B3 thymoma, 1), whereas 16 of the 20 thymic carcinomas (80%) showed positive immunoreactivity.
  • Testing was positive for CD5 in 14 of the 20 thymic carcinomas (70%).
  • Furthermore, of the 40 specimens examined (either thymic or lung carcinoma) all 13 that were positive for both KIT and CD5 were thymic carcinomas, and 13 of the 16 that were negative for both were lung carcinomas.
  • CONCLUSION: KIT expression is a useful immunohistochemical marker for the diagnosis of thymic carcinoma, and its examination in combination with CD5 immunohistochemistry would greatly help in the differential diagnosis of primary thymic carcinoma from pulmonary squamous cell carcinoma.
  • Further investigations at a genetic level should be encouraged, not only to define the role of KIT in the oncogenesis of thymic epithelial tumors, but also to establish target-based therapy.
  • [MeSH-major] Carcinoma / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis. Thymoma / metabolism. Thymus Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002927.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


43. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Solitary fibrous tumor of the thymus with local invasiveness and pleural dissemination: report of a case. Ann Thorac Cardiovasc Surg; 2007 Jun;13(3):198-202
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent an extended thymectomy via median sternotomy on suspicion of a thymoma.
  • The tumor was resected with the entire thymic tissue, and the invaded lung and pericardium were resected en-bloc.
  • Histopathologically, the lesion mainly consisted of non-atypical spindle-shaped tumor cells in a so-called "patternless pattern" with various densities of collagenous background.
  • Epithelial markers such as CAM 5.2 and AE1/AE3 were negative.
  • She is well without recurrence 3 months after the operation.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592430.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vimentin
  •  go-up   go-down


44. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, Lane HY: Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. J Psychopharmacol; 2009 Nov;23(8):937-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V-akt murine thymoma viral oncogene homolog 1 (AKT1) is a serine/threonine kinase known as protein kinase B.
  • One hundred and twenty newly hospitalised patients with acutely exacerbated schizophrenia who had never been treated by atypical antipsychotics were recruited.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635704.001).
  • [ISSN] 1461-7285
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


45. Amano H, Yamada T, Jujoh T, Kuroda F, Sakao S, Tada Y, Kurosu K, Kasahara Y, Tanabe N, Takiguchi Y, Tatsumi K: [Case of thymic carcinoid associated with multiple endocrine neoplasia type I treated effectively with chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):855-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of thymic carcinoid associated with multiple endocrine neoplasia type I treated effectively with chemotherapy].
  • He had a past history of hyperparathyroidism, for which he underwent surgery in 1994, and also had a family history in that his sister had multiple endocrine neoplasia type 1 (MEN1).
  • He was given a diagnosis of MEN I on genetic testing.
  • Chest CT revealed a mediastinal mass 4 cm in maximum dimension, and an atypical carcinoid was diagnosed according to mediastinal biopsy findings.
  • Although there are some cases of MEN-related thymoma treated by surgery, a case which successfully responded to chemotherapy alone is thought to be extremely rare.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / complications. Carcinoid Tumor / drug therapy. Multiple Endocrine Neoplasia Type 1 / complications. Thymus Neoplasms / complications. Thymus Neoplasms / drug therapy


46. Mizukami T, Hamamoto M, Orihashi K, Sueda T: Atypical presentation of xanthoma mimicking thymoma. Ann Thorac Surg; 2007 Mar;83(3):1205
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of xanthoma mimicking thymoma.
  • [MeSH-major] Abdomen. Thymoma / diagnosis. Thymus Neoplasms / diagnosis. Xanthomatosis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307501.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Winder T, Schuster A, Becherer A, Gasser K, De Vries A, Gruber-Moesenbacher U, Muendlein A, Drexel H, Lang A: Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT. Nuklearmedizin; 2010;49(5):N41-3
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Thymoma / drug therapy. Thymoma / radiography. Thymus Neoplasms / drug therapy. Thymus Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931150.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement